

07-19-02

1648
#6
Elec/Audit
5/26/02



Express Mail No.: EV 003 684 879 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Schneider and Klein

Confirmation No.: 7849

RECEIVED

Application No.: 09/955,006

Group Art Unit: 1648

JUL 23 2002

Filed: September 17, 2001

Examiner: B. Li

TECH CENTER 1600/2900

For: INHIBITION OF THE SRC KINASE
FAMILY PATHWAY AS A METHOD OF
TREATING HBV INFECTION AND
HEPATOCELLULAR CARCINOMA

Attorney Docket No.: 5914-084-999

#104-280.

**PRELIMINARY AMENDMENT AND RESPONSE TO RESTRICTION
REQUIREMENT UNDER 35 U.S.C. § 121**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the outstanding Office Action mailed June 18, 2002, please consider the amendments and remarks below. Applicants submit herewith: (a) an Information Disclosure Statement; (b) a Form PTO-1449 entitled "List of References Cited By Applicant" listing References AA-CR; (c) a copy of References AA-CR; and (d) an Appendix setting forth the claims as of entry of the instant Amendment, attached hereto as Exhibit A.

IN THE CLAIMS

Please cancel claims 1-21, without prejudice.

Please add new claims 22-30 as follows:

22. A method for treating Hepatitis B virus (HBV) infection or inhibiting HBV virus replication comprising administering a compound to an HBV-infected patient that modulates the level of cytosolic calcium.

amended
Sub. B

3003560
NY2 1335521.1